PHONE: 517.536.8210
FAX: 517.536.8205


TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Posts by TPPS

Winter 2018 Newsletter

A Note from the President The Super Bowl may be over, but our team is always training to compete against Super Bugs! Super bugs, or multi-drug resistant bacteria, are bacteria that cannot be killed using two or more antibiotics. Any species of bacteria can become a super bug, and misusing antibiotics is the leading factor contributing to this growing problem. Our winning streaks – bacteria on agar plates. A 2015 White House Report identified several super bug threats, many of which we use in our research here at TransPharm. We have validated studies using carbapenem-resistant enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), Acinetobacter, and many other super bugs. Have a question about which pathogens and models we specialize in? Contact us at your convenience. There are no half-time shows here; we work around the clock to complete studies for our fans. We don’t have turf or a stadium, but we pride ourselves on being champions in our field for the past 10 years. Several of our clients have published data on novel therapeutics to combat super bugs, and we think that’s something worth cheering for. Daniel Ross President & CEO In the Lab Recently, we have had several requests for our murine model of cecal ligation and puncture (CLP). CLP is the gold standard for inducing and studying sepsis, a serious condition characterized by systemic inflammation in response to widespread infection. More than 1.5 million Americans get sepsis each year, with about 250,000 of those patients dying annually ( To perform CLP, the cecum and adjoining instestine are exposed and the cecum is tightly ligated at its base below the ileo-cecal valve (top photo). Then, the cecum is punctured with a needle (bottom photo) and gently squeezed to extrude a small amount of feces from the puncture sites. The cecum is returned to the peritoneal cavity. Between 6 and 12 hours post-procedure, mice develop clinical signs of sepsis including lethargy, and diarrhea. Death occurs between 24 and 60 hours post-CLP, and mortality rates are predictable based on the size of the needle used for cecal perforation. Contact us for a no-obligation quote and professional consultation. Santiago R. Lopez, Ph.D. Chief Scientific Officer Come see us at ASM Microbe 2018! Members of the TransPharm team will be attending the American Society for Microbiology (ASM) Microbe...

Read More

Entrepreneurial plunge pays off for former Pfizer employees

Dan and Samantha Ross had just built a 4,000-square-foot log cabin for themselves in Jackson County when their employer, the drug giant Pfizer Inc., announced it was closing its sprawling campus in Ann Arbor. They could have taken another position with Pfizer in Connecticut, but they had no intention of leaving. “I knew what I wasn’t going to do, and that was move,” said Dan Ross. So the couple took an entrepreneurial plunge. Together, they founded TransPharm Preclinical Solutions LLC, a fast-growing biotech company based in Napoleon Township, a small community in southern Jackson County. Read...

Read More

Handling deadly diseases, Michigan company earns $12 million in first 10 years

NAPOLEON TWP., MI – The hit item is usually the freezer – which is kept at minus 80 degrees – when Daniel Ross takes school groups through TransPharm Preclinical Solutions. Most people in the community haven’t heard of his business and don’t know what it does, said Ross, president and CEO. He shows students around to bring awareness to the work that’s happening in their small town. “We don’t have to be in a big city,” said Marci Peek, contract and protocol specialist. “In little Napoleon, Michigan, we have clients all over the world.” TransPharm has 10 full-time employees and 101 clients in 13 countries. Located in rural Napoleon Township, the life sciences company reached its 10-year anniversary on Jan. 2.  Read...

Read More

Fall 2017 Newsletter

A Note from the President The year is coming to a close and 2018 is right around the corner. It’s hard to believe, but January will mark TransPharm’s 10-year anniversary. Our company started with just three employees, but ten years later we have quadrupled in size. The total revenue our first year was $147k; now we do over $2 million annually. Time flies when you’re having fun! To celebrate our landmark anniversary and as a thank you to our clients, we are offering 10% off all studies booked by December 21st. See below for more details. Also, we’d like to remind you that TransPharm will be closed starting Monday, December 25th and will reopen on Tuesday, January 2nd. The last day for animal deliveries is December 18th, with studies ending on the 22nd. Studies for early January (and any that you wish to be 10% off!) should be booked by December 21st. We will be checking email periodically, and this is the best way to reach us during our break. We wish you and yours a joyous holiday season and a happy new year. Daniel Ross President & CEO 10% Off ALL Studies! Celebrate our 10-year anniversary with 10% off! All studies booked* by 12/21/2017 are eligible for the discount. Contact Marci for a quote today! *Signed quotes and a purchase order must be received by end of business on Thursday, December 21, 2017. In the Lab TransPharm has added a new animal model of induced chronic osteomyelitis (bone infection). Osteomyelitis results in pain, loss of mobility, and significant morbidity. Current treatment requires prolonged antibiotic therapy and surgical debridement of sequestra (dead bone). Due to poor drug penetration into the bone and an increase in antibiotic-resistant bacteria, there is an urgent need for novel therapeutics. Our model serves as a screening tool to identify which antimicrobials are most clinically efficacious. Animals are challenged via injection into the cancellous bone marrow through the anterior surface of the proximal tibia (see photo). The infection is allowed to incubate for up to 4 weeks before the tibia is harvested for CFU enumeration. The induced chronic osteomyelitis model is currently available for S. aureus and S. epidermidis infections in Sprague-Dawley rats. Additional validations are available...

Read More

Summer 2017 Newsletter

A Note from the President It’s been a busy summer here at TransPharm and we are on track for another record year. Our team has been hard at work and we’re excited to share an inside look at what we do. The video below gives a great overview of our role in preclinical infectious disease research. It highlights our niche focus – animal models of bacteria, viruses, parasites, and fungi – which has cultivated an expertise that sets us apart from other contract research organizations. As specialists, we can serve as professional consultants to help you design a study that meets both your needs and your budget. You’ll also get a glimpse of our state-of-the-art laboratory and animal care facilities, as well as hear about how we manage such quick turn-around times for our clients. We have a passion for knowledge and scientific discovery and feel honored to play even a small part in the drug development process. It is our goal that our work will contribute to new and potentially life-saving therapies. We hope you enjoy the video and don’t forget to subscribe to our YouTube channel to see future content. Daniel Ross President & CEO In the Lab We are searching for TransPharm’s Next Top Model! Our team has been focused on validating new murine models of infectious disease, including Haemophilus influenzae pneumonia, Staphylococcus epidermidis peritonitis, Streptococcus pyogenes soft tissue infection, and Acinetobacter baumannii deep wound infection. Upcoming validations will follow-up on the 2017 summer internship program projects as well as validating new comparators against H. influenzae, P. acnes, and VRE. Contact us today to request a validation or no-obligation quote. Speaking of our internship program, it was featured in a recent edition of the Brooklyn Exponent. All four of our 2017 interns – Paige, Brandon, Jen, and Trevor – did a fantastic job in the lab. We are looking forward to meeting next year’s applicants! Santiago R. Lopez, Ph.D. Chief Scientific Officer Publications Many of our clients have published their research and acknowledged TransPharm’s role in their work. Check out a few of the manuscripts and poster presentations based on studies we’ve completed, including a P. acnes skin infection, a pulmonary model of Pseudomonas aeruginosa, a C. difficile gastrointestinal infection, as well as models of candidiasis, aspergillosis, and cecal ligation and puncture...

Read More